Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,080.97 -4.22 (-0.39%)
Streaming Delayed Price Updated: 11:16 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug ↗
The FDA approved a Wegovy pill as the first oral GLP-1 treatment for weight loss. 
Via Investor's Business Daily
News headline image
Novo Nordisk Stock Soars After Hours As FDA Greenlights Wegovy Pill For Weight Loss ↗
The Danish drugmaker expects to launch the pill in the U.S. in January. 
Via Stocktwits
News headline image
The Incretin Empire: Eli Lilly’s (LLY) Path to a $1 Trillion Market Cap and Beyond
As of December 22, 2025, the global equity markets are witnessing a historic recalibration of the healthcare sector. For decades, the "Trillion Dollar Club" was an exclusive enclave for Silicon... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Eli Lilly - Momentum Near 52‑Week High As Trade Engine Flags Moderate Strength ↗
Eli Lilly's stock is nearing its 52-week high due to strong momentum and positive news, but upcoming earnings and regulatory developments are crucial for sustaining this performance. 
Via Talk Markets
News headline image
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? ↗
Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader. 
Via The Motley Fool
News headline image
2 Profitable Stocks with Exciting Potential and 1 Facing Challenges
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
ELI LILLY & CO (NYSE:LLY) Combines Strong Earnings Momentum with Bullish Technical Setup ↗
Eli Lilly (LLY) combines explosive earnings growth with a strong technical uptrend, offering a high-momentum investment opportunity within a supportive chart setup. 
Via Chartmill
News headline image
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era
As the final weeks of 2025 unfold, the biotechnology sector is undergoing a fundamental transformation, shifting from a pure-play innovation market to one increasingly dictated by the "physical"... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees &#39;Room For Stock Upside&#39; With $3 Billion In Sales By 2026 ↗
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug. 
Via Benzinga
News headline image
1 No-Brainer Growth S&P Index Fund to Buy Right Now for Less Than $500 ↗
This is a quick and easy way to invest in growth. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Better Buy in 2026: UnitedHealth Group or Eli Lilly? ↗
These industry titans have gone in opposite directions this year; is that likely to change? 
Via The Motley Fool
Topics Fraud
News headline image
The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'
As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Worried About the Stock Market in 2026? These 3 Stocks Did Well During the Last Bear Market. ↗
The stocks listed here were all up more than 19% in 2022, while the S&P 500 crashed. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
New Obesity Medicine Association Initiative Aims to Scale High-Impact Obesity Healthcare Improvements Nationwide
Centennial, Colorado--(Newsfile Corp. - December 18, 2025) - The Obesity Medicine Association (OMA) is pleased to announce a new multi-phase... 
Via Newsfile
News headline image
Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics ↗
Lilly’s Orforglipron is eligible for a fast-track review by the FDA in treating obesity. 
Via Stocktwits
News headline image
Better Buy in 2026: Pfizer or Eli Lilly? ↗
These two stocks have been going in opposite directions over the past few years. 
Via The Motley Fool
Topics World Trade
News headline image
Main Street’s High-Stakes Gamble: Retail Traders Double Down as Inflation Cools to 2.7%
NEW YORK — In a stunning reversal of the "higher-for-longer" narrative that dominated much of 2025, the Bureau of Labor Statistics released its November Consumer Price Index (CPI) report today,... 
Via MarketMinute
Topics Artificial Intelligence Economy Regulatory Compliance
News headline image
Why Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 "ATTAIN-MAINTAIN" trial, which evaluated the... 
Via StockStory
News headline image
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss ↗
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo. 
Via Benzinga
News headline image
The Weight of a Trillion: Inside Eli Lilly’s Pharmaceutical Hegemony
On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold... 
Via PredictStreet
Topics Economy World Trade
News headline image
Eli Lilly's Weight-Loss Pill Succeeds In A First-Of-Its-Kind Study ↗
Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off. 
Via Investor's Business Daily
News headline image
Eli Lilly Scores Another Major Win: Time to Buy? ↗
The company is running circles around its competition. 
Via The Motley Fool
News headline image
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk ↗
These two healthcare stocks have strong growth prospects, but they've been going in opposite directions. 
Via The Motley Fool
News headline image
The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now ↗
It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
3 Unstoppable Vanguard ETFs to Buy Even if There's a Stock Market Sell-Off in 2026 ↗
These three growth stock-heavy ETFs offer a contrarian way to invest in a potential stock market sell-off. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall... 
Via MarketMinute
Topics Intellectual Property
News headline image
1 Bold Prediction for Viking Therapeutics in 2026 ↗
Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.